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discriminating Parkinson’s disease and progressive 
supranuclear palsy: a retrospective study based on 
1.5 and 3 T MRI
Waseem Mehmood 
Nizamani1
Fatima Mubarak1
Muhammad Danish 
Barakzai1
Muhammad Saad Ahmed2
1Department of Radiology, Aga Khan 
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Objective: The objective of the study was to assess magnetic resonance (MR) planimetric 
measurements and MR parkinsonism index (MRPI) in differentiating progressive supranuclear 
palsy (PSP) from Parkinson’s disease (PD) using 1.5 and 3 T MRI scanner.
Subjects and methods: After ethical approval was obtained, analysis of 34 consecutive 
patients with PSP, 34 patients with PD and 34 healthy controls (HCs) was performed. HCs 
were age-matched adults without any history of neurodegenerative disease or movement 
disorders. Retrospective data from the past 10 years (from January 2006 to December 2015) 
were obtained from the Hospital Information Management System, and informed consent was 
obtained from all participants. The measurements of pons area–midbrain area ratio (P/M) and 
MCP width–superior cerebellar peduncle (SCP) width ratio (MCP/SCP) were used, and MRPI 
was calculated by the formula ([P/M]×[MCP/SCP]).
Results: Midbrain area and SCP width in patients with PSP (19 males, 15 females; mean age 
=66.7 years) were significantly (P<0.001) smaller than in patients with PD (20 males, 14 females; 
mean age =66.7 years) and control participants (17 males, 17 females; mean age =66.1 years). 
P/M and MCP/SCP were significantly higher in patients with PSP than in patients with PD and 
control participants. All measurements showed some overlap of values between patients with 
PSP and patients from PD group and control participants. MRPI value was significantly higher 
in patients with PSP (mean 21.00) than in patients with PD (mean 9.50; P<0.001) and control 
participants (mean 9.6; P<0.001), without any overlap of values among groups. No correlation 
was found between the duration of disease, PSP rating scale, PSP staging system and MRPI in 
this study. No patient with PSP received a misdiagnosis when the index was used (sensitivity and 
specificity, 100%).
Conclusion: MRPI should be made an essential part of all MRI brain reporting whenever 
differentiation between PD and PSP is sought for.
Keywords: cognitive dysfunction, movement disorders, progressive supranuclear palsy, Par-
kinsonism Index
Introduction
Progressive supranuclear palsy (PSP), also called Steele–Richardson–Olszewski syn-
drome, is a neurodegenerative disorder represented by supranuclear vertical gaze palsy, 
postural instability and frequent falls, parkinsonian features, cognitive impairment and 
speech disturbances.1 PSP is characterized by early and severe postural instability, 
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with falls in the first year of disease onset, supranuclear gaze 
palsy and slowing of vertical saccades. Other characteristics 
include rapid disease progression and reduced response to 
medication.
For decades, the diagnosis of parkinsonian disorders has 
relied upon the presence and progression of characteristic 
clinical features. To establish a diagnostic consensus, various 
sets of clinical criteria have been proposed for diagnosis of 
parkinsonian disorders such as Parkinson’s disease (PD) and 
PSP.2–4 Clinical criteria proposed by the National Institute for 
Neurological Disorders and Society for PSP describe catego-
rization of PSP into possible, probable and definite subtypes, 
depending on mandatory inclusion, supportive and exclusion 
criteria in detail.3 Idiopathic PD, PSP and multiple system 
atrophy can be difficult to be differentiated clinically, particu-
larly early in the disease course.5 On the other hand, clinical 
diagnostic classification of PD based on Movement Disorder 
Society Clinical Diagnostic Criteria for PD was proposed in 
2015 by Postuma et al.4 Movement Disorder Society diagnostic 
criteria defined “parkinsonism” as the presence of bradykinesia 
with at least one of rest tremor or rigidity. Once parkinsonism 
is diagnosed, supportive criteria for idiopathic PD include a 
clear response to dopaminergic therapy and/or the presence of 
levodopa-induced dyskinesias.4
Despite these suggestive features, in many cases, all these 
clinical findings are not as clear-cut as it ideally could be and 
a great degree of overlap exists.6 Various pathologic data 
have shown considerable false-positive and false-negative 
results if diagnosis is made only on the basis of clinical 
criteria. Misdiagnosis is especially common during the early 
stages of these disorders due to lack of classic clinical signs.2 
Undoubtedly, the definitive diagnostic test is neuropathologic 
confirmation for both the conditions, which is not possible 
routinely; however, there is a dire need for an alternative but 
highly accurate diagnostic tool to predict the prognosis and 
to guide management of these patients.
Magnetic resonance imaging (MRI) has a substantial role 
in the diagnosis of various movement disorders. Conventional 
MRI demonstrates symptomatic causes of parkinsonism, but 
does not show any specific finding in PD. In parkinsonism 
variants such as PSP, MRI reveals characteristic patterns of 
regional atrophy combined with signal changes or microstruc-
tural changes in the basal ganglia, pons, middle cerebellar 
peduncle and superior cerebellar peduncle (SCP) and cerebral 
subcortical white matter. PSP has unique morphologic and 
underlying molecular pathologic changes. The cellular char-
acteristic is neurofibrillary degeneration; the distribution and 
intensity of damage to brainstem and basal ganglia are used 
to pathologically describe the disorder. A large number of 
studies aimed at evaluating the possible contribution of MRI 
to the diagnosis have been performed. The high spatial and 
contrast resolution combined with the multiplanar capability 
of MRI enables in vivo demonstration of loss of the bulk of 
central nervous system structures with the regional distribu-
tion pattern typical of some movement disorders.7,8 Pathologic 
findings suggest that midbrain and SCPs are atrophic in PSP; 
on the other hand, all these brain structures are spared in PD. 
The major changes are in substantia nigra, pars compacta and 
reticulata, globus pallidus, subthalamic nucleus, midbrain and 
reticular formation of pons. Degeneration of midbrain and 
pontine structures leads to identifiable changes of brainstem 
atrophy on MRI, with widening of cerebral aqueduct, thinning 
of midbrain tegmentum and fourth ventricular dilatation.9,10 We 
utilized the MR parkinsonism index, which is calculated by 
multiplying the pons area–midbrain area ratio by the middle 
cerebellar peduncle width–SCP width ratio, for the combined 
assessment at routine MR imaging of four brain structures dif-
ferently involved in atypical parkinsonian syndromes. Magnetic 
resonance parkinsonism index (MRPI) has been proved to be 
an extremely reliable measure to distinguish patients with PSP 
from those with PD and control subjects, on an individual basis.9
International studies have shown that PSP is more familiar 
than previously recognized, that it is frequently misdiagnosed 
and that it may initially present to various medical subspe-
cialties.1 The aim of this study was to evaluate the diagnostic 
accuracy of MRPI which reflects structural anatomic changes 
measured by quantitative MRI analysis and to propose 
MRI-based criteria to help the clinician to recognize these 
parkinsonian syndromes. Objective quantifications of brain 
structures using linear, surface and volumetric measurements 
have been reported before in international literatures;6–11 
however, no local data has been ever reported regarding 
parkinsonism variants due to lack of awareness and clinical 
knowledge. To our knowledge, not a single research was 
ever performed on the diagnostic workup of PSP in  Pakistan. 
Therefore, taking this into consideration, this research 
would play a pioneer role in the subspecialty of movement 
disorder and quantitative MRI parameters at a local level. 
Our study will broaden the research horizon, spark a new 
hope of research on this topic resulting in more availability 
of local data and would be helpful in assessing implication 
of international results in this part of world.
Subjects and methods
Patients’ inclusion and control 
participants
This study was conducted at the Aga Khan University Hospital, 
Karachi, Pakistan, after collecting retrospective data from past 
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10 years (from January 2006 to December 2015) from the Hos-
pital Information Management System. Data were obtained 
after getting approval from the ethical review committee of Aga 
Khan University. Consent was obtained from all the patients at 
the time of admission and was maintained by ERC.
Data of 34 consecutive patients with clinically proven 
PSP, 34 patients with clinically proven PD and 34 healthy 
controls (HCs) were obtained. HCs were age-matched adults 
without any history of neurodegenerative disease or movement 
disorders. Findings of neurologic examination were obtained 
in each case. Established consensus criteria were fulfilled for 
the diagnosis of PSP3 and PD.5 All HCs had normal findings 
at neurologic examination. MRI images of brain were blindly 
reviewed by consultant neuroradiologist with at least 5 years 
of clinical experience. The measurements of middle cerebellar 
peduncle (MCP)–SCP width ratio (MCP/SCP) and pons–
midbrain area ratio (P/M) were used for calculating MRPI; 
MRPI was calculated by the formula ([P/M]×[MCP/SCP]).
MRI protocols
All MRIs were performed using MAGNETOM® Avanto 
Siemens 1.5 T MR Scanner and Toshiba Vantage TITAN™ 
3 T MR Scanner. All MR brain included axial intermediate-
weighted and T2-weighted dual-echo fast spin echo (rep-
etition time msec/echo time msec, 3500/10.2, 85; section 
thickness, 4 mm; frequency- and phase-encoding matrix, 
288×224), transverse fluid-attenuated inversion recovery 
(repetition time msec/echo time msec/inversion time msec, 
8000/120/2000; slice thickness, 4 mm; frequency- and phase-
encoding matrix, 256×224), transverse T2-weighted gradient 
echo (500/15; section thickness, 4 mm; frequency- and phase-
encoding matrix, 256×192; flip angle, 20°) and T1-weighted 
volumetric spoiled gradient echo (15.2/6.8; slice thickness, 
0.6 mm; frequency- and phase-encoding matrix, 256×256; 
flip angle, 15°) sequences. A volumetric block of 45 mm 
(0.9 mm section thickness) tangent to the floor of the fourth 
ventricle was placed on the midsagittal plane to cover both 
SCPs completely. The resulting images in oblique-coronal 
plane were utilized for SCP width quantification.
Image interpretation
All the images were interpreted by an experienced consultant 
neuroradiologist and his clinical fellow in the Department of 
Radiology using Rogan-Delft Zillion Picture Archiving and 
Communication System on standard DICOM display moni-
tor. The measurements of midbrain and pontine areas were 
performed on the midsagittal plane of T2-weighted MRI in all 
patients and HC participants, as described by Massey et al.5
The reference image was taken as the midsagittal section 
of MR brain. Right and left MCPs were recognized on the 
parasagittal planes, and the distance between superior and 
inferior borders of MCPs was measured. Mean values were 
obtained from the right and left MCPs. Measurements of 
SCPs were obtained on coronal fluid-attenuated inversion 
recovery images which are an essential part of MRI brain 
protocol. Images were visually inspected in the antero-
posterior direction to identify the first view on which the 
inferior colliculi and SCPs were separated. Average mea-
surements of linear distance between the medial and lateral 
borders of both SCPs at the middle of their extension were 
calculated (Figure 1). The pons–midbrain area ratio (P/M) 
and the MCP–SCP width ratio (MCP/SCP) were used for 
calculating an index that was termed as MRPI as follows: 
([P/M]×[MCP/SCP]).8
Statistical analyses
Statistical analysis was performed with statistical software 
(SPSS for Windows, version 21.0; IBM Corporation, 
Armonk, NY, USA). The analysis used c2 test followed by 
evaluation with pairwise test for comparison of two propor-
tions, corrected according to Bonferroni method and one-way 
analysis of variance, and evaluation with unpaired t-test and 
Bonferroni correction to compare age at examination, dis-
ease duration and age at onset. To assess the differences in 
Hoehn–Yahr scores and MRI measurements among groups, 
the Kruskal–Wallis test was used, followed by evaluation 
with the Mann–Whitney U test for multiple comparisons.
Results
Thirty-four cases with clinical diagnosis of PD (20 males, 
14 females; mean age =66.76±6.28; disease duration 
=6.3±3.86), 34 cases with clinical diagnosis of PSP (19 
males, 15 females; mean age =66.76±6.27; disease duration 
=6.6±2.82) and 34 HC participants (17 males, 17 females; 
mean age =66.14±7.53) were studied. In all cases, age varied 
from 58 to 82 (mean age 66.55±6.66) years.
Table 1 shows the demographic information of both 
patients’ groups and HC participants involved in this study. 
MR planimetric measurements of all three groups are pre-
sented in Table 2. All the measurements are the mean values 
calculated from individual measurements. Midbrain mea-
surement revealed significantly smaller mean midbrain area 
of 96.02 mm2 in PSP subjects in comparison to PD patients 
(mean area of 145.58 mm2) and HC participants (mean area 
of 149.41 mm2). Similarly, the mean width of SCP in patients 
with PSP was 2.81 mm, which was significantly smaller than 
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Figure 1 MRI brain images of this study in orthogonal planes showing measurement annotations and appropriate planes for measurements.
Notes: (A) Coronal FLAIR image shows measurement of right superior cerebellar peduncle. (B) Midsagittal T2W image represents the area of midbrain and pons. (C) T1W 
parasagittal image depicts middle cerebellar peduncle measurement.
Abbreviation: FLAIR, fluid-attenuated inversion recovery.
A B
C
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4.33 mm in PD patients and 4.36 mm in HC participants 
(P<0.001). The analysis of MCP dimensions showed that 
PSP, PD and HC cases had mean values of 12.78, 12.81 and 
13.4 mm, respectively. No significant difference was found 
between PD and HC participants regarding individual mea-
surements of midbrain, pons, SCP and MCP. Comparison 
of P/M and MCP/SCP ratio among the three groups demon-
strated significantly higher values in patients with PSP than 
HC participants and PD patients (Figures 2 and 3).
All obtained measurements showed minor overlap of val-
ues between patients with PSP and PD and HC participants. 
MRPI was significantly higher in PSP patients (mean 21) than 
PD patients (mean 9.50; P<0.001) and HC participants (mean 
9.6; P<0.001), without overlapping of values among groups, 
as shown in Figure 4. No correlation was found between the 
duration of disease, PSP rating scale, PSP staging system and 
MRPI in this study. None of the patients with PSP received 
a misdiagnosis when this index was applied (sensitivity and 
specificity, 100%). However, in this study, we found the 
sensitivity and specificity of MCP/SCP ratio to be 85% and 
92.86%, respectively, and that the P/M ratio was 85.71% 
sensitive in differentiating PSP from PD, but showed more 
specificity (97.67%) and diagnostic accuracy (87.87%) due 
to overlapping individual values (Table 3).
Pair wise comparative analysis using MRPI values 
between different groups showed statistical significance 
(P<0.001) between PD and PSP patients and between PSP 
patients and HC participants. On the other hand, no statistical 
significance was found between PD patients and HC partici-
pants in pair wise comparison using MRPI values (Table 4).
Discussion
Among the neurodegenerative parkinsonian disorders, PSP 
is the second most common after idiopathic Parkinson’s 
disease.2 Since levodopa responsiveness is poor and clini-
cal deterioration is faster in PSP, it is important to be able 
to differentiate between idiopathic Parkinson’s disease and 
PSP.12 It has been suggested that MR measurements of several 
brainstem structures could overcome the limitations inherent 
in the clinical diagnostic criteria for PSP.8,12,13
In addition, quantitative measurements of brainstem 
structures have been reported to be useful in differentiating 
patients with PSP from those with PD.19 Different brainstem 
measurements include P/M and MCP/SCP ratios; however, 
one study demonstrated that MRPI was more accurate than 
P/M in differentiating patients with possible PSP from those 
with PD and, as we have discussed earlier, that MRPI is cal-
culated by the formula ([P/M]×[MCP/SCP]).8,20
Recent studies have shown extensive research work on 
MRPI, and a new automatic method for calculating the MRPI 
is formulated based on automatic algorithm, which helps in 
the early diagnosis of PSP with less time and more accuracy.21
In a very interesting study, the researchers have compared 
morphometric markers (midbrain area, pons to midbrain area 
ratio and MRPI) with Diffusion Tensor Imaging parameters 
(infratentorial structures) and volumetric analysis (thalamus, 
putamen and pallidus nuclei), and surprisingly found that the 
morphometric assessment is the best single diagnostic marker 
and should be routinely included in the neuroradiologic work-
up of parkinsonian patients.22
The role of quantitative MRI in vascular parkinsonism 
was also analyzed by several studies, which revealed MRPI 
may represent an accurate tool in differentiating PSP from 
vascular parkinsonism, however, it is not discussed in detail 
in this article.23
The role of regional distribution of white matter damage 
by using Diffusion Tensor Imaging also improves the diag-
nostic accuracy of MRI in the diagnosis of supranuclear palsy, 
not independently, but only in combination with MRPI.24
In this study, we analyzed those neural structures that were 
primarily involved in PSP, in order to differentiate them from 
others. Atrophy of midbrain is the typical pathologic finding 
Table 1 Demographic data of PD and PSP patients along with 
healthy control participants involved in this study
HC PD PSP
No of participants 34 34 34
Mean age (years) at 
evaluation
66.14±7.53 66.76±6.28, 66.76±6.27
Sex Male 17 20 19
Female 17 14 15
Duration of disease (years) – 6.3±3.86 6.6±2.82
Hoehn–Yahr score – 2.5 (1.5–5) 4 (3–5)
Abbreviations: HC, healthy control; PD, Parkinson’s disease; PSP, progressive 
supranuclear palsy.
Table 2 MR planimetric measurements in three different subgroups of this study
Participant groups Midbrain area (mm2) Pons area (mm2) SCP width (mm) MCP width (mm)
PSP (n=34) 96.02±13.47 430.73±49.02 2.81±0.47 12.78±1.57
PD (n=34) 145.58±30.17 455.29±60.76 4.33±0.68 12.81±1.99
HC (n=34) 149.41±12.53 457.64±38.06 4.36±0.43 13.4±1.31
Note: Values are medians and mean ± SD.
Abbreviations: HC, healthy control; MCP, middle cerebellar peduncle; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; SCP, superior cerebellar peduncle.
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in PSP patients.10 Neuroimaging findings15,16 confirmed the 
diagnostic value of presence of midbrain atrophy in PSP 
patients and concluded that measurement of midbrain area 
could help in differentiation of PSP patients from PD patients. 
Our findings, however, reveal that measurement of midbrain 
area is unsuccessful to aid in distinction, on an individual 
basis, of patients with PSP from PD. In this study, the aver-
age midbrain area of PSP patients was significantly smaller 
than those of PD cases and HC participants, but individual 
values of midbrain area overlapped significantly with others.
MRPI is significantly higher in PSP patients than in HCs 
and PD cases. MRPI is proposed to distinguish PSP from 
PD on an individual basis. MRPI had a very high sensitivity, 
specificity and positive predictive value, when a cut-off of 
13.5 was taken to discriminate rest of parkinsonian disorders 
from PSP.9,25
In this study, PSP had a mean MRPI of 21; on the other 
hand, the mean MRPI was 9.6 in HC and 9.5 in PD. The mean 
age at onset of the disease was 66.76 years, which is com-
parable to earlier studies. The average disease duration was 
found to be 6.6 years. Other studies have found a higher age at 
examination and longer disease duration. Therefore, MRPI can 
be helpful in differentiating PSP from PD in the early stages of 
the disease.25–27 However, further studies should be performed 
with large number of patients to obtain more reliable figures.
In this study, the midbrain area in PSP (mean 96.02 mm2) 
was significantly less than in PD (mean 145.58 mm2) and HC 
(mean 149.41 mm2). The individual values of midbrain area 
Figure 2 Box plot of P/M ratio in patients with PSP. 
Notes: Median is shown as a line across each box, and vertical solid lines (whiskers) show lower and upper values: PSP patients (median =4.50; range, 3.29–6.11), PD patients 
(median =3.13; range, 2.35–3.91), control participants (median =3.0; range, 2.37–3.93).
Abbreviations: P/M, pons area–midbrain area ratio; PD, Parkinson’s disease; PSP, progressive supranuclear palsy.
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overlapped with other groups, making the differentiation dif-
ficult on an individual basis. This study also revealed slightly 
reduced mean pons area in PSP (430.73 mm2) than in PD 
(455.29 mm2). Our results were fairly comparable with the 
findings of previous international studies.25,28,29
The mean SCP width in PSP was 2.81 mm, which was 
remarkably less than those of PD (4.33 mm) and HC (4.36 
mm) subjects. Based on previous studies, mean SCP width 
<3 mm is thought to be associated with PSP. We did not 
find considerable difference in mean SCP width in PD and 
HC. Similarly, due to overlapping of individual values, SCP 
width could not differentiate PSP from other groups on an 
individual basis.9,15,25,29
Our data also suggest that mean MCP width in PSP (12.78 
mm) was smaller than those of PD (12.81 mm) and HC (13.4 
mm), but with a minor difference. Comparable results were 
observed in the data from previous studies.9,25,28,29
Comparing the MRPI values of our study and previous 
studies, MRPI of 21.4 was calculated by Morelli et al,25 
20.7 by Longoni et al,29 18.63 by Hussl et al,31 24.56 by 
Quattrone et al9 and 23.48 by Sankhla et al.30 In this study, 
mean MRPI was 21 in PSP, 9.5 in patients with PD and 9.6 
in HC, a finding that is supportive with the results of other 
studies.9,25,29,31
As mentioned earlier, single brain measurements are 
unable to aid in differentiating PSP from other groups; rather, 
combined assessment of all four brain structures involved in 
this neurodegenerative process is proven to be more helpful. 
Single measurement of P/M ratio can differentiate PSP from 
PD and HCs in some cases9,15 The mean P/M ratio in PSP 
(4.54) was significantly higher than PD (3.18) and HC (3.08), 
with the values overlapping in individual cases. Overlap-
ping of values between the PSP and other groups was also 
encountered in Morelli et al’s study.25
Figure 3 Box plot of MCP/SCP ratio in PSP patients (median =4.75; range, 3.14–6.35), PD patients (median =2.97; range, 1.92–4.77), control participants (median =3.0; 
range, 2.38–4.29).
Abbreviations: P/M, pons area–midbrain area ratio; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; SCP, superior cerebellar peduncle.
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We found, MRPI as 100% sensitive, specific and accurate 
in distinguishing PSP from PD, when a cut-off level of 13.5 
was used. Our results showed higher statistical values than 
previous studies that also showed close to 90% sensitivity 
and specificity.
Morelli et al also reported that P/M ratio was unsuccess-
ful to distinguish PSP from PD on an individual basis. They 
found a relatively higher sensitivity of 92.9%, but lower 
specificity, and diagnostic accuracy of 85.3% and 86.8%, 
respectively.25 Hussl et al also reported relatively low sensi-
tivity and diagnostic accuracy for the same.1,31
Correlation between MRPI and the disease duration was 
found by some researches,9,25 but we did not find any cor-
relation of MRPI values with disease duration.
MRPI improved the diagnostic accuracy much more 
than that seen with the use of P/M ratio in discriminating 
PSP from PD because of the combined assessment of four 
brain structures involved in neurodegenerative disorders. 
Figure 4 Box plot of MRPI in PSP patients (median =21; range, 12.92–30.56), PD patients (median =9.5; range, 5.89–14.9), control participants (median =9.6; range, 6.67–
14.29). MRPI values are higher in PSP patients compared to PD and HC.
Abbreviations: HC, healthy controls; MRPI, Magnetic Resonance Parkinsonism Index; PD, Parkinson’s disease; PSP, progressive supranuclear palsy.
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Table 3 Sensitivity and specificity of MRPI for the differentiation 
of PSP and PD
Statistical values MRPI  
value
MCP/SCP  
value
P/M  
value
Cut-off value ≥13.5 ≥3.2 ≥4.2
Sensitivity (%) 100 85 85.71
Specificity (%) 100 92.86 91.67
PPV (%) 100 94.44 94.74
NPV (%) 100 81.25 78.57
Diagnostic accuracy (%) 100 88.23 87.87
Abbreviations: MRPI, Magnetic Resonance Parkinsonism Index; NPV, negative 
predictive value; PD, Parkinson’s disease; P/M, pons area–midbrain area ratio; 
PPV, positive predictive value; PSP, progressive supranuclear palsy; SCP, superior 
cerebellar peduncle.
Table 4 All pairwise multiple comparison procedures taking 
MRPI values
Comparison P<0.001 Difference
PSP vs PD Yes Significant
PSP vs control Yes Significant
Control vs PD No Not significant
Note: P values were determined with Mann–Whitney U test.
Abbreviations: MRPI, Magnetic Resonance Parkinsonism Index; PD, Parkinson’s 
disease; PSP, progressive supranuclear palsy.
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Thus, atrophy of midbrain and SCP suggested the presence 
of PSP. These brain structures are usually not involved in PD. 
However, calculation of MRPI is more time consuming than 
calculation of the P/M ratio because it involves measurement 
of additional brain structures.
Our limitations were that we used clinical criteria for the 
diagnosis of PSP and we did not have a pathologic confirma-
tion. Thus, it is likely that in some patients, the clinical diag-
nosis may be inaccurate. However, sensitivity and specificity 
of clinical diagnostic criteria for PSP are well documented, 
so the chances are unlikely. However, it is an important con-
sideration that so far MRI brain is not a complete substitution 
for clinical and neuropathologic assessment. Thus, clinicians 
need to be acquainted with the diagnostic criteria for PSP 
and be sufficiently aware of the application of this method 
in patients’ clinical context.
Conclusion
In cases of clinically unclassifiable parkinsonism, MRPI 
is a reliable and accurate marker to predict the presence 
of PSP. In comparison to individual measurements such as 
midbrain to pons ratio or SCP to middle cerebellar peduncle 
ratio, it has superior diagnostic value as it accounts both 
measurements. It is also more reliable in early detection 
and can predict the disease on an individual basis without 
overlap.
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